Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q01974
UPID:
ROR2_HUMAN
Alternative names:
Neurotrophic tyrosine kinase, receptor-related 2
Alternative UPACC:
Q01974; Q59GF5; Q5SPI5; Q9HAY7; Q9HB61
Background:
Tyrosine-protein kinase transmembrane receptor ROR2, also known as Neurotrophic tyrosine kinase, receptor-related 2, plays a pivotal role in chondrocyte formation and cartilage development. It phosphorylates YWHAB, promoting osteogenesis and bone formation. Additionally, ROR2 may act as a receptor for WNT5A, potentially inhibiting WNT3A-mediated signaling.
Therapeutic significance:
ROR2 is implicated in Brachydactyly B1 and autosomal recessive Robinow syndrome, diseases characterized by skeletal abnormalities. Understanding ROR2's role could lead to novel treatments for these conditions.